Professor | Dingwei Ye | Asia Growth Partners

	Upload Avatar (500 x 500)
Name	Dingwei Ye
Contact Information	dwyeli@163.com
Language ability	Chinese, English
Province	Shanghai

Upload Avatar (500 x 500)

Name

Dingwei Ye

Contact Information

dwyeli@163.com

Language ability

Chinese, English

Province

Shanghai

University/Lab Affiliation and Title	Fudan University
Faculty	Biomedical Sciences
Academic Background & Achievements	1981-09 to 1986-07: Bachelor's Degree in Military Medicine, Second Military Medical University 1990-09 to 1993-07: Master's Degree in Urology, Second Military Medical University 1997-09 to 2000-07: Doctoral Degree in Urology, Second Military Medical University 2015: National Health and Family Planning Commission Outstanding Young and Middle-aged Expert 2013: State Council Special Allowance 2011: Shanghai Leading Talent 2011: Shanghai Medical Leading Talent 2011: Enders Medical Science and Technology Award for Outstanding Achievement 2010: Fudan University Excellent Talent Dean's Award 2009: Shanghai Excellent Discipline Leader A-level Plan 1996: Wu Jieping Urology Medical Award
Work Experience	1986.7 to 2002.5: Second Military Medical University Changhai Hospital, Urology Department (Resident Physician, Attending Physician, Associate Chief Physician, Associate Professor, Master's Supervisor) 1996.9 to 1998.12: MD Anderson Cancer Center, USA (Visiting Scholar, Postdoctoral Fellow) 2002.5 to Present: Fudan University Cancer Hospital (Director of Urology Department, Chief Physician, Professor, Doctoral Supervisor) 2007.10 to Present: Vice President, Fudan University Cancer Hospital
Awards	2016: Second Prize of the Chinese Anti-Cancer Association Science and Technology Award (First Author) 2016: Gold Award for Excellent Invention in the Shanghai Excellent Invention Selection Competition 2012: First Prize of National Science and Technology Progress Award (Third Author) 2012: First Prize of Shanghai Science and Technology Progress Award (First Author) 2012: Second Prize of Ministry of Education Science and Technology Progress Award (First Author) 2012: First Prize of Shanghai Medical Association Science and Technology Award (First Author) 2010: First Prize of Shanghai Science and Technology Progress Award (First Author) 2010: Second Prize of Chinese Anti-Cancer Association Science and Technology Award (First Author) 2010: Second Prize of Chinese Medical Science and Technology Progress Award (First Author) 2010: First Prize of Higher Education Science and Technology Progress Award (First Author) 2010: Second Prize of Shanghai Medical Science and Technology Award (First Author)

University/Lab Affiliation and Title

Fudan University

Faculty

Biomedical Sciences

Academic Background & Achievements

1981-09 to 1986-07: Bachelor's Degree in Military Medicine, Second Military Medical University
1990-09 to 1993-07: Master's Degree in Urology, Second Military Medical University
1997-09 to 2000-07: Doctoral Degree in Urology, Second Military Medical University
2015: National Health and Family Planning Commission Outstanding Young and Middle-aged Expert
2013: State Council Special Allowance
2011: Shanghai Leading Talent
2011: Shanghai Medical Leading Talent
2011: Enders Medical Science and Technology Award for Outstanding Achievement
2010: Fudan University Excellent Talent Dean's Award
2009: Shanghai Excellent Discipline Leader A-level Plan
1996: Wu Jieping Urology Medical Award

Work Experience

1986.7 to 2002.5: Second Military Medical University Changhai Hospital, Urology Department (Resident Physician, Attending Physician, Associate Chief Physician, Associate Professor, Master's Supervisor)
1996.9 to 1998.12: MD Anderson Cancer Center, USA (Visiting Scholar, Postdoctoral Fellow)
2002.5 to Present: Fudan University Cancer Hospital (Director of Urology Department, Chief Physician, Professor, Doctoral Supervisor)
2007.10 to Present: Vice President, Fudan University Cancer Hospital

Awards

2016: Second Prize of the Chinese Anti-Cancer Association Science and Technology Award (First Author)
2016: Gold Award for Excellent Invention in the Shanghai Excellent Invention Selection Competition
2012: First Prize of National Science and Technology Progress Award (Third Author)
2012: First Prize of Shanghai Science and Technology Progress Award (First Author)
2012: Second Prize of Ministry of Education Science and Technology Progress Award (First Author)
2012: First Prize of Shanghai Medical Association Science and Technology Award (First Author)
2010: First Prize of Shanghai Science and Technology Progress Award (First Author)
2010: Second Prize of Chinese Anti-Cancer Association Science and Technology Award (First Author)
2010: Second Prize of Chinese Medical Science and Technology Progress Award (First Author)
2010: First Prize of Higher Education Science and Technology Progress Award (First Author)
2010: Second Prize of Shanghai Medical Science and Technology Award (First Author)

Areas of Focus	Molecular biology, immunology, and bioinformatics methods to study signal transduction, tumor microenvironment, tumor metabolism, and epigenetic regulation mechanisms in urological and male reproductive system tumors including prostate cancer, kidney cancer, bladder cancer, and penile cancer
Publications	Androgen and epidermal growth factor down-regulate cyclin-dependent kinase inhibitor p27Kip1 and costimulate proliferation of MDA PCa 2a and MDA PCa 2b prostate cancer cells, Ye, D., Mendelsohn, J., and Fan, Z., 1999 Augmentation of a humanized anti-HER2 mAb 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225, Ye, D., Mendelsohn, J., and Fan, Z., 1999 Predicting regional lymph node metastasis in Chinese patients with penile squamous cell carcinoma: the role of histopathological classification, tumor stage and depth of invasion, Dai, B., Ye, D. W., Kong, Y. Y., Yao, X. D., Zhang, H. L., and Shen, Y. J., 2006 The prognostic significance of p53, Ki-67, epithelial cadherin and matrix metalloproteinase-9 in penile squamous cell carcinoma treated with surgery, Zhu, Y., Zhou, X. Y., Yao, X. D., Dai, B., and Ye, D. W., 2007 A multiplex model of combining gene-based, protein-based, and metabolite-based with positive and negative markers in urine for the early diagnosis of prostate cancer, Cao, D. L., Ye, D. W., Zhang, H. L., Zhu, Y., Wang, Y. X., and Yao, X. D., 2011 Genome-wide association study in Chinese men identifies two new prostate cancer risk loci at 9q31.2 and 19q13.4, Xu, J., Mo, Z., Ye, D., Wang, M., Liu, F., Jin, G., Xu, C., Wang, X., Shao, Q., Chen, Z., Tao, Z., Qi, J., Zhou, F., Wang, Z., Fu, Y., He, D., Wei, Q., Guo, J., Wu, D., Gao, X., Yuan, J., Wang, G., Xu, Y., Wang, G., Yao, H., Dong, P., Jiao, Y., Shen, M., Yang, J., Ou-Yang, J., Jiang, H., Zhu, Y., Ren, S., Zhang, Z., Yin, C., Gao, X., Dai, B., Hu, Z., Yang, Y., Wu, Q., Chen, H., Peng, P., Zheng, Y., Zheng, X., Xiang, Y., Long, J., Gong, J., Na, R., Lin, X., Yu, H., Wang, Z., Tao, S., Feng, J., Sun, J., Liu, W., Hsing, A., Rao, J., Ding, Q., Wiklund, F., Gronberg, H., Shu, X. O., Zheng, W., Shen, H., Jin, L., Shi, R., Lu, D., Zhang, X., Sun, J., Zheng, S. L., and Sun, Y., 2012 Livin expression may be regulated by miR-198 in human prostate cancer cell lines, Ye, L., Li, S., Ye, D., Yang, D., Yue, F., Guo, Y., Chen, X., Chen, F., Zhang, J., and Song, X., 2013 Prognostic value of carbonic anhydrase IX expression in penile squamous cell carcinoma: a pilot study, Zhu, Y., Zhou, X. Y., Yao, X. D., Zhang, S. L., Dai, B., Zhang, H. L., Shen, Y. J., and Ye, D. W., 2013 Prostate cancer: alkaline phosphatase velocity in nonmetastatic CRPC, Zhu, Y., and Ye, D. W., 2014 Nutritional screening is strongly associated with overall survival in patients treated with targeted agents for metastatic renal cell carcinoma, Gu, W., Zhang, G., Sun, L., Ma, Q., Cheng, Y., Zhang, H., Shi, G., Zhu, Y., and Ye, D., 2015 NADP(+)-IDH Mutations Promote Hypersuccinylation that Impairs Mitochondria Respiration and Induces Apoptosis Resistance, Li, F., He, X., Ye, D., Lin, Y., Yu, H., Yao, C., Huang, L., Zhang, J., Wang, F., Xu, S., Wu, X., Liu, L., Yang, C., Shi, J., He, X., Liu, J., Qu, Y., Guo, F., Zhao, J., Xu, W., and Zhao, S., 2015 Two novel PRKCI polymorphisms and prostate cancer risk in an Eastern Chinese Han population

Areas of Focus

Molecular biology, immunology, and bioinformatics methods to study signal transduction, tumor microenvironment, tumor metabolism, and epigenetic regulation mechanisms in urological and male reproductive system tumors including prostate cancer, kidney cancer, bladder cancer, and penile cancer

Publications

Androgen and epidermal growth factor down-regulate cyclin-dependent kinase inhibitor p27Kip1 and costimulate proliferation of MDA PCa 2a and MDA PCa 2b prostate cancer cells, Ye, D., Mendelsohn, J., and Fan, Z., 1999
Augmentation of a humanized anti-HER2 mAb 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225, Ye, D., Mendelsohn, J., and Fan, Z., 1999
Predicting regional lymph node metastasis in Chinese patients with penile squamous cell carcinoma: the role of histopathological classification, tumor stage and depth of invasion, Dai, B., Ye, D. W., Kong, Y. Y., Yao, X. D., Zhang, H. L., and Shen, Y. J., 2006
The prognostic significance of p53, Ki-67, epithelial cadherin and matrix metalloproteinase-9 in penile squamous cell carcinoma treated with surgery, Zhu, Y., Zhou, X. Y., Yao, X. D., Dai, B., and Ye, D. W., 2007
A multiplex model of combining gene-based, protein-based, and metabolite-based with positive and negative markers in urine for the early diagnosis of prostate cancer, Cao, D. L., Ye, D. W., Zhang, H. L., Zhu, Y., Wang, Y. X., and Yao, X. D., 2011
Genome-wide association study in Chinese men identifies two new prostate cancer risk loci at 9q31.2 and 19q13.4, Xu, J., Mo, Z., Ye, D., Wang, M., Liu, F., Jin, G., Xu, C., Wang, X., Shao, Q., Chen, Z., Tao, Z., Qi, J., Zhou, F., Wang, Z., Fu, Y., He, D., Wei, Q., Guo, J., Wu, D., Gao, X., Yuan, J., Wang, G., Xu, Y., Wang, G., Yao, H., Dong, P., Jiao, Y., Shen, M., Yang, J., Ou-Yang, J., Jiang, H., Zhu, Y., Ren, S., Zhang, Z., Yin, C., Gao, X., Dai, B., Hu, Z., Yang, Y., Wu, Q., Chen, H., Peng, P., Zheng, Y., Zheng, X., Xiang, Y., Long, J., Gong, J., Na, R., Lin, X., Yu, H., Wang, Z., Tao, S., Feng, J., Sun, J., Liu, W., Hsing, A., Rao, J., Ding, Q., Wiklund, F., Gronberg, H., Shu, X. O., Zheng, W., Shen, H., Jin, L., Shi, R., Lu, D., Zhang, X., Sun, J., Zheng, S. L., and Sun, Y., 2012
Livin expression may be regulated by miR-198 in human prostate cancer cell lines, Ye, L., Li, S., Ye, D., Yang, D., Yue, F., Guo, Y., Chen, X., Chen, F., Zhang, J., and Song, X., 2013
Prognostic value of carbonic anhydrase IX expression in penile squamous cell carcinoma: a pilot study, Zhu, Y., Zhou, X. Y., Yao, X. D., Zhang, S. L., Dai, B., Zhang, H. L., Shen, Y. J., and Ye, D. W., 2013
Prostate cancer: alkaline phosphatase velocity in nonmetastatic CRPC, Zhu, Y., and Ye, D. W., 2014
Nutritional screening is strongly associated with overall survival in patients treated with targeted agents for metastatic renal cell carcinoma, Gu, W., Zhang, G., Sun, L., Ma, Q., Cheng, Y., Zhang, H., Shi, G., Zhu, Y., and Ye, D., 2015
NADP(+)-IDH Mutations Promote Hypersuccinylation that Impairs Mitochondria Respiration and Induces Apoptosis Resistance, Li, F., He, X., Ye, D., Lin, Y., Yu, H., Yao, C., Huang, L., Zhang, J., Wang, F., Xu, S., Wu, X., Liu, L., Yang, C., Shi, J., He, X., Liu, J., Qu, Y., Guo, F., Zhao, J., Xu, W., and Zhao, S., 2015
Two novel PRKCI polymorphisms and prostate cancer risk in an Eastern Chinese Han population

Molecular Biology Immunology Bioinformatics Signal Transduction Tumor Microenvironment Tumor Metabolism Epigenetic Regulation Prostate Cancer Kidney Cancer Bladder Cancer

Fei Chen - Fudan University

Shenglin Huang - Fudan University

Xinxin Huang - Fudan University

View All

Personal Information

Academic Information

Research

Contact us

No account yet?

Personal Information

Academic Information

Research

Contact us